Kiniksa Pharmaceuticals International, plc KNSA
94.71 USD +1.42 (+1.52%)
Nov 4, 2026, 12:15 PM EST
91.74 Day range 95.35
37.02 52-week range 98.48
- YTD
- +129.60%
- 1 year
- +145.74%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 109.43 +15.5% upside
Now 94.71
- Target (low)
- 98.00
- Target (mean)
- 109.43
- Target (high)
- 134.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.275 | 0.14 – 0.41 | 0.17 | +61.8% | 306.56M | +51.7% | 4 |
| Next quarter | 0.44 | 0.29 – 0.55 | 0.27 | +63.0% | 313.78M | +46.4% | 4 |
| Current year | 1.50 | 1.22 – 1.91 | 0.75 | +99.3% | 1.05B | +55.0% | 4 |
| Next year | 2.18 | 1.59 – 2.80 | 1.50 | +46.0% | 1.32B | +26.2% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 28, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Oct 28, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Oct 28, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 30, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Jul 29, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 29, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 29, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 29, 2026 | Citigroup | Maintained | Buy | Buy |
| Jul 23, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Jul 13, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jun 29, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 29, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Apr 29, 2026 | Citigroup | Maintained | Buy | Buy |
| Apr 29, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 29, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Apr 28, 2026 | Jefferies | Maintained | Buy | Buy |
| Apr 16, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Feb 25, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Feb 25, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Feb 19, 2026 | Canaccord Genuity | Initiated | — | Buy |
| Jan 13, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Oct 29, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Oct 17, 2025 | Citigroup | Maintained | Buy | Buy |
| Oct 13, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Sep 29, 2025 | TD Cowen | Initiated | — | Buy |
| Sep 25, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 29, 2025 | Jefferies | Maintained | Buy | Buy |
| Jul 9, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Apr 29, 2025 | Jefferies | Maintained | Buy | Buy |
